A new sector analysis highlights a shift in biopharma deal structures, with more large transactions incorporating contingent milestone payments and “CVR”-style mechanics. The report says milestone-linked payouts have become more common in deals valued at $500 million or more since mid-2024, suggesting acquirers want tighter alignment to clinical, regulatory, licensing, and sales outcomes. The analysis notes that the prevalence of contingent value rights has increased compared with earlier periods, and that for deals above $1 billion, the share of agreements containing potential payouts reached around 70% across multiple recent quarters. The immediate effect for biotech companies and dealmakers is pricing complexity: valuation becomes more path-dependent, and diligence must sharpen around which milestones are likely to be met. For investors and operators, the broader signal is that risk is being redistributed through contract design as opposed to being fully priced upfront—especially as pipeline differentiation and regulatory uncertainty remain core drivers of biotech returns.